...
首页> 外文期刊>Calcified tissue international. >Skeletal alkaline phosphatase activity is primarily released from human osteoblasts in an insoluble form, and the net release Is inhibited by calcium and skeletal growth factors.
【24h】

Skeletal alkaline phosphatase activity is primarily released from human osteoblasts in an insoluble form, and the net release Is inhibited by calcium and skeletal growth factors.

机译:骨骼碱性磷酸酶活性主要以不溶形式从人成骨细胞释放,并且净释放受到钙和骨骼生长因子的抑制。

获取原文
获取原文并翻译 | 示例
           

摘要

Skeletal alkaline phosphatase (ALP) is anchored to membrane inositol-phosphate on the outer surface of osteoblasts. Although skeletal ALP activity in serum is, essentially, all in an anchorless (soluble) form, in vitro studies indicate that ALP can be released in either an anchorless, soluble form (e.g., by a phospholipase) or an anchor-intact, insoluble form (e.g., by vesicle exocytosis). The current studies were intended to define the contributions of each of these putative processes of ALP release and to assess the significance of regulation by calcium (Ca) and skeletal effectors. ALP activity was measured in serum-free medium from replicate cultures of human osteosarcoma (SaOS-2) cells and normal human bone cells. Temperature-sensitive phase distribution (in Triton X-114) allowed separation of soluble from insoluble ALP activity. Our studies revealed that most of the ALP activity released from SaOS-2 cells was in an insoluble form (78% +/- 8%), a percentage that was constant between 2 and 96 hours. A similar result was seen for normal human bone cells. Calcium had a negative, biphasic dose-dependent effect on net release of ALP activity: r = -0.85, P < 0.001 at 24 hours, with KIapparent values for biphasic inhibition of 20 and 300 mumol/l Ca. Of the skeletal effectors tested, insulin-like growth factor-II (IGF-II) had the greatest effect, decreasing the net release of ALP activity in a dose-dependent manner (r = -0.82, P < 0.005). Neither Ca nor IGF-II affected the distribution of soluble/insoluble ALP activity by more than 9%. IGF-II had no effect on extracellular ALP stability, but the addition of Ca to Ca-free cultures resulted in parallel losses of extracellular ALP activity and ALP immunoreactive protein (P < 0.001 for each). A similar effect was seen when Ca was added to Ca-free, cell-free, conditioned medium, but not when Ca was added to purified ALP, which is consistent with the general hypothesis that a Ca-dependent protease might be present in the cell-conditioned medium. Together, these data suggest that most of the ALP activity released from osteoblasts is insoluble (and, presumably, anchorless), net release of ALP activity is negatively regulated by Ca and skeletal growth factors, the effect of Ca may reflect Ca-dependent protease activity, and an exogenous (e.g., serum) phospholipase may be responsible for releasing ALP from its insoluble anchor.
机译:骨骼碱性磷酸酶(ALP)锚定在成骨细胞外表面的膜肌醇磷酸酯上。尽管血清中的骨骼肌ALP活性基本上全部为无锚定(可溶)形式,但体外研究表明ALP可以无锚定的可溶形式(例如,通过磷脂酶)或无锚定的不可溶形式释放(例如,通过囊泡胞吐作用)。当前的研究旨在确定ALP释放的每个假定过程的贡献,并评估钙(Ca)和骨骼效应因子调节的重要性。在来自人骨肉瘤(SaOS-2)细胞和正常人骨细胞的复制培养物中的无血清培养基中测量ALP活性。温度敏感的相分布(在Triton X-114中)允许将可溶性和不可溶性ALP活性分离。我们的研究表明,从SaOS-2细胞释放的大多数ALP活性都是不溶形式(78%+/- 8%),该百分比在2到96小时之间是恒定的。正常人的骨细胞也有类似的结果。钙对ALP活性的净释放具有负的,双相的剂量依赖性作用:r = -0.85,24小时时P <0.001,双相抑制的KIapparent值分别为20和300μmol/ lCa。在所测试的骨骼效应中,胰岛素样生长因子II(IGF-II)的作用最大,以剂量依赖性方式降低ALP活性的净释放(r = -0.82,P <0.005)。 Ca和IGF-II都不会影响可溶/不可溶ALP活性的分布超过9%。 IGF-II对细胞外ALP稳定性没有影响,但是在无钙培养物中添加Ca会导致细胞外ALP活性和ALP免疫反应蛋白的平行损失(每个P <0.001)。当将Ca添加到无Ca,无细胞的条件培养基中时,会看到类似的效果,但当将Ca添加到纯化的ALP中时却没有看到,这与细胞中可能存在Ca依赖性蛋白酶的一般假设是一致的。条件培养基。总之,这些数据表明成骨细胞释放的大多数ALP活性是不溶的(并且大概是无锚的),ALP活性的净释放受Ca和骨骼生长因子的负调控,Ca的作用可能反映了Ca依赖性蛋白酶的活性,并且外源性(例如血清)磷脂酶可能负责从其不溶性锚释放ALP。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号